- Home
- SPPP vs PBYI Comparison
SPPP vs PBYI Comparison
Compare SPPP & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPPP
- PBYI
- Stock Information
- Founded
- SPPP 2011
- PBYI 2010
- Country
- SPPP Canada
- PBYI United States
- Employees
- SPPP N/A
- PBYI N/A
- Industry
- SPPP
- PBYI Biotechnology: Pharmaceutical Preparations
- Sector
- SPPP
- PBYI Health Care
- Exchange
- SPPP NYSE
- PBYI Nasdaq
- Market Cap
- SPPP 172.2M
- PBYI 167.3M
- IPO Year
- SPPP N/A
- PBYI N/A
- Fundamental
- Price
- SPPP $11.65
- PBYI $3.38
- Analyst Decision
- SPPP
- PBYI Strong Buy
- Analyst Count
- SPPP 0
- PBYI 1
- Target Price
- SPPP N/A
- PBYI $7.00
- AVG Volume (30 Days)
- SPPP 183.3K
- PBYI 379.0K
- Earning Date
- SPPP 01-01-0001
- PBYI 07-31-2025
- Dividend Yield
- SPPP N/A
- PBYI N/A
- EPS Growth
- SPPP N/A
- PBYI 143.51
- EPS
- SPPP N/A
- PBYI 0.77
- Revenue
- SPPP N/A
- PBYI $232,709,000.00
- Revenue This Year
- SPPP N/A
- PBYI N/A
- Revenue Next Year
- SPPP N/A
- PBYI N/A
- P/E Ratio
- SPPP N/A
- PBYI $4.36
- Revenue Growth
- SPPP N/A
- PBYI 2.68
- 52 Week Low
- SPPP $8.55
- PBYI $2.23
- 52 Week High
- SPPP $11.39
- PBYI $4.13
- Technical
- Relative Strength Index (RSI)
- SPPP 73.98
- PBYI 48.53
- Support Level
- SPPP $11.36
- PBYI $3.25
- Resistance Level
- SPPP $11.58
- PBYI $3.39
- Average True Range (ATR)
- SPPP 0.27
- PBYI 0.15
- MACD
- SPPP 0.03
- PBYI -0.03
- Stochastic Oscillator
- SPPP 89.54
- PBYI 22.22
About SPPP SPROTT PHYS PLATINUM & PALLADIUM
Sprott Physical Platinum & Palladium Tr invests and holds all of its assets in physical platinum and palladium bullion. The company seeks to provide a secure, convenient, and exchange-traded investment alternative for investors interested in holding physical platinum and palladium bullion without the inconvenience that is typical of a direct investment in physical bullion. The Trust invests mainly in long-term holdings of unencumbered, fully allocated, physical platinum and palladium bullion.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.